Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Wilcox

Showing results (451-460 of 454) with videos related to

Pageof 46
Sort By:
You have reached the last page of results.This site can display upto 454 results.
Annals of the American Thoracic Society|June 28, 2016
High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF StudyChristopher J Ryerson, Pat G Camp, Neil D Eves, et al.
The European Respiratory Journal|March 11, 2022
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registryNathan Hambly, M Malik Farooqi, Anna Dvorkin-Gheva, et al.
Lancet (London, England)|October 11, 2005
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialJohn A Dormandy, Bernard Charbonnel, David J A Eckland, et al.
American Journal of Respiratory and Critical Care Medicine|April 30, 2019
Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary FibrosisCamille Moore, Rachel Z Blumhagen, Ivana V Yang, et al.
Pageof 46

Showing results (451-460 of 454) with videos related to

Sort By:
Pageof 46
You have reached the last page of results.This site can display upto 454 results.
Annals of the American Thoracic Society|June 28, 2016
High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF StudyChristopher J Ryerson, Pat G Camp, Neil D Eves, et al.
The European Respiratory Journal|March 11, 2022
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registryNathan Hambly, M Malik Farooqi, Anna Dvorkin-Gheva, et al.
Lancet (London, England)|October 11, 2005
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialJohn A Dormandy, Bernard Charbonnel, David J A Eckland, et al.
American Journal of Respiratory and Critical Care Medicine|April 30, 2019
Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary FibrosisCamille Moore, Rachel Z Blumhagen, Ivana V Yang, et al.
Pageof 46